HI
TVTX icon

Handelsinvest Investeringsforvaltning’s Travere Therapeutics TVTX Stock Holding History

Handelsinvest Investeringsforvaltning’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-80,000
Closed -$1.61M – 122
2019
Q2 		$1.61M Buy
80,000
+13,084
+20% +$258K 0.34% 64
2019
Q1 		$1.51M Hold
66,916
– – 0.33% 60
2018
Q4 		$1.51M Buy
66,916
+16,916
+34% +$421K 0.38% 58
2018
Q3 		$1.44M Buy
+50,000
New +$1.43M 0.29% 61

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Handelsinvest Investeringsforvaltning's TVTX Position: Q3 2019 in Review

Handelsinvest Investeringsforvaltning sold out of Travere Therapeutics (TVTX) in Q3 2019, closing a stake of 80,000 shares — an estimated $1.61M sold.

Handelsinvest Investeringsforvaltning first reported a position in TVTX in Q3 2018 and held it in 4 quarters. The position peaked at $1.61M in Q2 2019. 130 funds tracked by Wall St. Rank hold TVTX as of Q3 2019.

  • Handelsinvest Investeringsforvaltning reported no remaining Travere Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Handelsinvest Investeringsforvaltning sold 80,000 Travere Therapeutics shares in Q3 2019, an estimated $1.61M.
  • Handelsinvest Investeringsforvaltning first reported a position in Travere Therapeutics in Q3 2018 and held it in 4 quarters.
  • Handelsinvest Investeringsforvaltning's Travere Therapeutics position peaked at $1.61M in Q2 2019.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2019.

Based on Handelsinvest Investeringsforvaltning's 13F filing for Q3 2019, filed 22 Oct 2019.